Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon

Bone Marrow Transplant. 2007 Aug;40(3):261-6. doi: 10.1038/sj.bmt.1705706. Epub 2007 Jun 11.

Abstract

The conditioning regimens for autologous SCT (auto-SCT) lead to impairment of the immune system and concomitant increase in susceptibility to infections. We studied the recovery of cellular immunity by in vitro analysis of T-cell proliferation and cytokine production profiles during the first 15 months after auto-SCT in patients with multiple myeloma and non-Hodgkin's lymphoma. PBMC were collected at 6, 9 and 15 months after transplantation and stimulated with a combination of CD2 and CD28 monoclonal antibodies, with PHA or with tetanus toxoid as recall antigen. A multiplex enzyme linked immunoassay was used to determine levels of Th1 cytokines IL-2, IFN-gamma and tumour-necrosis factor-alpha (TNF-alpha), Th2 cytokines IL-4, IL-5 and IL-13, the regulatory cytokine IL-10 and the proinflammatory cytokines IL-1alpha, IL-1beta, IL-6 and the chemokine IL-8. T-cell proliferation progressively increased from 6 to 15 months after auto-SCT. Overall, cytokine production increased after auto-SCT. Production of Th2 cytokines IL-5 and IL-13 was superior to production of Th1 cytokines IFN-gamma and TNF-alpha. We hypothesize that prolonged impairment of IFN-gamma production might contribute to the relatively high incidence of viral infections after auto-SCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antigens / immunology*
  • Antigens / pharmacology
  • CD2 Antigens / immunology
  • CD2 Antigens / pharmacology
  • CD28 Antigens / immunology
  • CD28 Antigens / pharmacology
  • Cell Proliferation / drug effects
  • Cytokines / immunology
  • Female
  • Follow-Up Studies
  • Humans
  • Immunity, Cellular
  • Incidence
  • Interferon-gamma / immunology*
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / immunology*
  • Lymphoma, Non-Hodgkin / therapy
  • Male
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / therapy
  • Phytohemagglutinins / immunology
  • Phytohemagglutinins / pharmacology
  • Stem Cell Transplantation*
  • Tetanus Toxoid / immunology
  • Tetanus Toxoid / pharmacology
  • Th1 Cells / immunology*
  • Th2 Cells / immunology*
  • Time Factors
  • Transplantation Conditioning / adverse effects
  • Transplantation, Autologous
  • Virus Diseases / etiology
  • Virus Diseases / immunology

Substances

  • Antibodies, Monoclonal
  • Antigens
  • CD2 Antigens
  • CD28 Antigens
  • Cytokines
  • Phytohemagglutinins
  • Tetanus Toxoid
  • Interferon-gamma